Healthcare Industry News: Alzheimer's
News Release - September 14, 2009
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention StudyFindings from 52-week study presented at major European psychiatry congress demonstrate time to relapse significantly longer with SAPHRIS
ISTANBUL, Sept. 14 (Healthcare Sales & Marketing Network) -- Schering-Plough Corporation (NYSE: SGP ) today reported final results of a SAPHRIS(R) (asenapine) long-term schizophrenia relapse prevention clinical study. In the double-blind phase of the study, time to relapse or impending relapse, the primary efficacy endpoint, was significantly longer with SAPHRIS than with placebo (P < 0.0001). At the end of the double-blind phase, significantly fewer patients had relapsed with SAPHRIS than with placebo, 12 percent vs. 47 percent (P < 0.0001). In addition, the time to treatment discontinuation for any reason, a secondary efficacy assessment, was significantly longer with SAPHRIS than placebo (P < 0.001). These results were presented at a major European psychiatry congress in Istanbul, Turkey.
"Relapse rates can be high among patients with schizophrenia. Symptoms return in more than half of all patients by two years and in more than 80 percent by five years," said Steven Potkin, M.D., professor, department of psychiatry and human behavior, University of California, Irvine. "It is important that clinicians have new treatment options that not only effectively manage the symptoms of schizophrenia and are well tolerated by patients, but that also can help delay relapse."
SAPHRIS was approved by the U.S. Food and Drug Administration (FDA) on August 13 for the acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults. SAPHRIS can be used as a first-line treatment and is the first psychotropic drug to receive initial approval for both of these indications simultaneously. In Europe, a Marketing Authorization Application (MAA) for asenapine, under the brand name SYCREST(R), is currently under review by the European Medicines Agency (EMEA) for the treatment of schizophrenia and manic episodes associated with bipolar I disorder. The application will follow the Centralized Procedure. These long-term relapse prevention data are included in the European application and will be submitted to FDA in a supplemental application. Schering-Plough has reported additional top-line results for SAPHRIS in long-term clinical studies and additional clinical studies with SAPHRIS are ongoing.
"Schizophrenia is a serious, debilitating disease affecting millions of people worldwide, and there is a need for effective new medications," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute. "These results provide important new data for SAPHRIS and provide physicians insight into the treatment of patients responding to SAPHRIS."
About the Relapse Prevention Study
The Phase III relapse prevention study was a placebo-controlled, double-blind, clinical trial with a randomized withdrawal design that evaluated the long-term efficacy and safety of a sublingually administered investigational dose of SAPHRIS (5 or 10 mg BID) compared to placebo in prolonging time to relapse or impending relapse in patients with stable schizophrenia. A total of 700 patients entered open-label treatment with SAPHRIS for up to 26 weeks. Of these, a total of 386 patients met criteria for stabilization on SAPHRIS and were randomized to treatment in the 26-week double-blind, placebo-controlled phase of the trial.
The primary endpoint of the double-blind phase of the trial - time to relapse or impending relapse - was defined as one of the following: 1) a PANSS (Positive and Negative Syndrome Scale) total score increase of equal to or greater than 20 percent from baseline in the double-blind phase and a CGI-S (Clinical Global Impression-Severity of Illness) score of equal to or greater than 4 at least two days within one week; 2) a PANSS score equal to or greater than 5 on "hostility" or "uncooperativeness" items or on "unusual thought content," "conceptual disorganization" or "hallucinatory behavior" items, and a CGI-S score equal to or greater than 4 (at least two days within one week); or 3) the investigator's judgment of worsening symptoms or increased risk of violence to self (including suicide) or others.
In the double-blind phase of the trial, the incidence of treatment-emergent and treatment-related adverse events was higher with placebo than with SAPHRIS. The most frequently reported adverse events were anxiety (8.2 percent with SAPHRIS vs. 10.9 percent with placebo), increased weight (6.7 percent with SAPHRIS vs. 3.6 percent with placebo) and insomnia (6.2 percent with SAPHRIS vs. 13.5 percent with placebo). Worsening schizophrenia was reported as an adverse event by 4.6 percent of SAPHRIS-treated patients and 16.1 percent of placebo-treated patients; the incidence of adverse events that were also considered a relapse was 7.2 percent with SAPHRIS and 26.6 percent with placebo. The incidence of clinically significant weight gain (equal to or greater than 7 percent increase from baseline) was 3.7 percent with SAPHRIS and 0.5 percent with placebo (mean +/- SD weight change was 0.0+/-4.3 kg and -1.2+/-4.0 kg, respectively). The incidence of markedly abnormal prolactin values (greater than 4 times the upper limit of normal) was 2.8 percent with SAPHRIS and 4.2 percent with placebo.
About SAPHRIS (asenapine)
SAPHRIS is a psychotropic agent approved in the United States for the acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults. The recommended starting dose of SAPHRIS for the acute treatment of schizophrenia is 5 mg sublingually twice daily. In controlled trials, there was no suggestion of added benefit with a higher dose, but there was a clear increase in certain adverse reactions. The safety of doses above 10 mg twice daily has not been evaluated in clinical studies. While there is no body of evidence available to answer the question of how long a patient with schizophrenia should remain on SAPHRIS, it is generally recommended that responding patients continue beyond the acute response.
Schering-Plough acquired asenapine in November 2007 through its acquisition of Organon BioSciences, which developed the product.
Important Safety Information about SAPHRIS
Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5 percent compared to a rate of 2.6 percent in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. SAPHRIS is not approved for the treatment of patients with dementia-related psychosis.
Cerebrovascular Adverse Events: There was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. SAPHRIS is not approved for the treatment of patients with dementia-related psychosis.
Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported with administration of antipsychotic drugs, including SAPHRIS. NMS can cause hyperpyrexia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia. Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis) and acute renal failure. Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems.
Tardive Dyskinesia (TD): The risk of developing TD and the potential for it to become irreversible may increase as the duration of treatment and the total cumulative dose increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Prescribing should be consistent with the need to minimize TD. If signs and symptoms appear, discontinuation should be considered.
Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases associated with ketoacidosis, hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Patients with risk factors for diabetes mellitus who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of and during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should also undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the antipsychotic drug.
Weight Gain: In short-term schizophrenia and bipolar mania trials, there were differences in mean weight gain between SAPHRIS-treated and placebo-treated patients. In a 52 week study, the proportion of patients with an equal to or greater than 7 percent increase in body weight was 14.7 percent.
Orthostatic Hypotension and Syncope and Other Hemodynamic Effects: SAPHRIS may induce orthostatic hypotension and syncope. SAPHRIS should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, conditions which would predispose them to hypotension and in the elderly. SAPHRIS should be used cautiously when treating patients who receive treatment with other drugs that can induce hypotension, bradycardia, respiratory or central nervous system depression. Monitoring of orthostatic vital signs should be considered in all such patients, and a dose reduction should be considered if hypotension occurs.
Leukopenia, Neutropenia, and Agranulocytosis: In clinical trial and postmarketing experience, events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents, including SAPHRIS. Patients with a pre-existing low white blood cell count (WBC) or a history of leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and SAPHRIS should be discontinued at the first sign of a decline in WBC in the absence of other causative factors.
QT Prolongation: SAPHRIS was associated with increases in QTc interval ranging from 2 to 5 msec compared to placebo. No patients treated with SAPHRIS experienced QTc increases of equal to or greater than 60 msec from baseline measurements, nor did any experience a QTc of equal to or greater than 500 msec. SAPHRIS should be avoided in combination with other drugs known to prolong QTc interval, in patients with congenital prolongation of QT interval or a history of cardiac arrhythmias, and in circumstances that may increase the occurrence of torsades de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval.
Hyperprolactinemia: Like other drugs that antagonize dopamine D2 receptors, SAPHRIS can elevate prolactin levels, and the elevation can persist during chronic administration. Galactorrhea, amenorrhea, gynecomastia and impotence have been reported in patients receiving prolactin-elevating compounds.
Seizures: SAPHRIS should be used cautiously in patients with a history of seizures or with conditions that lower seizure threshold, e.g., Alzheimer's dementia.
Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia. SAPHRIS is not indicated for the treatment of dementia-related psychosis, and should not be used in patients at risk for aspiration pneumonia.
Potential for Cognitive and Motor Impairment: Somnolence was reported in patients treated with SAPHRIS. Patients should be cautioned about performing activities requiring mental alertness, such as operating hazardous machinery or operating a motor vehicle, until they are reasonably certain that SAPHRIS therapy does not affect them adversely.
Suicide: The possibility of suicide attempt is inherent in psychotic illnesses and bipolar disorder. Close supervision of high-risk patients should accompany drug therapy. Prescriptions for SAPHRIS should be written for the smallest quantity of tablets in order to reduce the risk of overdose.
SAPHRIS is not recommended in patients with severe hepatic impairment.
Co-administration of SAPHRIS with strong CYP1A2 inhibitors (fluvoxamine) or compounds which are both CYP2D6 substrates and inhibitors (paroxetine) should be done with caution.
Commonly observed adverse reactions (incidence equal to or greater than 5 percent and at least twice that for placebo) were: Patients with Schizophrenia: akathisia, oral hypoesthesia and somnolence. Patients with Bipolar Disorder: somnolence, dizziness, extrapyramidal symptoms other than akathisia and weight increase.
Please see full prescribing information at www.SAPHRIS.com.
Schizophrenia is an often chronic and disabling brain disorder that is characterized by various symptom domains, such as so-called positive symptoms (including hallucinations, delusions and disordered thinking) as well as negative symptoms, cognitive impairment and other general psychopathological symptoms (such as anxiety or depression). This clinically heterogeneous disorder has a lifetime prevalence of approximately 1 percent, affecting about 24 million people worldwide, including more than two million people in the United States and more than four million people in Europe.
About Bipolar I Disorder
Bipolar I disorder (also known as manic-depressive disorder) is a chronic, episodic illness characterized by mania (episodes of elevated moods, extreme irritability, decreased sleep and increased energy), depression (overwhelming feelings of sadness, suicidal thoughts), or a combination of both. It is the sixth leading cause of disability in the world, affecting approximately 1 percent of adults, including 10 million Americans.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the clinical development of, the commercial plans for and the potential market for SAPHRIS/SYCREST. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including uncertainties in the regulatory process, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A. "Risk Factors" in the Company's second quarter 2009 10-Q, filed July 24, 2009.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.